Originally developed to treat type 2 diabetes, GLP-1 receptor agonists have rapidly become a cornerstone of obesity management, fundamentally altering the trajectory of U.S. healthcare. Their surging popularity is driving shifts in clinical practice, insurance coverage dynamics, and public health policy nationwide.
